NGM Biopharmaceuticals Appoints Helen S. Kim as Chief Business Officer
September 1st 2009
South San Francisco, CA – September 1, 2009 – NGM Biopharmaceuticals, a privately held biotechnology company focused on developing novel therapies for metabolic diseases, announced appointment of Helen S. Kim as chief business officer. Ms. Kim will be responsible for managing the Company’s business functions including corporate and business development initiatives.
Ms. Kim brings over 20 years of industry experience to NGM. Most recently, Ms. Kim served as Director and chief executive officer of privately held TRF Pharma, Inc. Previously, she was the chief executive officer and President of Kosan Biosciences where she restructured and repositioned the company prior to successfully selling it to Bristol- Myers Squibb in 2008. Ms. Kim’s additional industry experience includes executive management positions at Affymax, Onyx Pharmaceuticals, and Chiron Corporation. In addition, Ms. Kim also served as chief program officer for the Gordon and Betty Moore Foundation where she successfully created and implemented initiatives to transform healthcare delivery in acute care hospitals to reduce mortality and morbidities. Ms. Kim received a B.S. in Chemical Engineering from Northwestern University and a M.B.A. from the University of Chicago.
“Helen will contribute to the development and execution of Company’s business strategy,” said David V. Goeddel, Ph.D., NGM’s acting chief executive officer and director. “Strategic partners will be important as we build our pipeline of novel biotherapeutics. Helen brings a wealth of experience in creation of strategic collaborations with pharmaceutical and biotech companies.”
Ms. Kim stated, “I am especially impressed by NGM’s excellent scientific reputation and the Company’s proprietary, biology-based discovery approach. The Company has already made significant progress in identifying new, clinically relevant targets that impact the underlying etiology of type 2 diabetes. I admire the strong commitment of NGM’s team and investors to build a company that will be differentiated by its robust pipeline of first-in-class biotherapeutics that will redefine and enhance patient outcomes.”
About NGM Biopharmaceuticals
NGM Biopharmaceuticals, Inc. is a privately held drug discovery company dedicated to developing transformational medicines that significantly improve human health. NGM is the first company to establish a proprietary discovery platform and generate a differentiated pipeline based on understanding and leveraging the relationship between bariatric gastric bypass surgery in type 2 diabetic patients and observed post-surgical therapeutic benefits. NGM has established a unique research platform designed to provide a rich pipeline of new targets that NGM can use to develop novel treatments for metabolic diseases, such as obesity, muscle wasting and cardiovascular disease in addition to diabetes. Founded in 2008, NGM has an elite executive team with broad experience in building and managing biotechnology companies, and is supported by investors who are committed to the Company’s success. NGM is headquartered in South San Francisco. For more information, please visit the Company’s website at www.ngmbio.com.